Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals.

TitleLower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals.
Publication TypeJournal Article
Year of Publication2011
AuthorsAnthony DD, Umbleja T, Aberg JA, Kang M, Medvik K, Lederman MM, Peters MG, Koziel MJ, Overton ET
JournalVaccine
Volume29
Issue19
Pagination3558-63
Date Published2011 Apr 27
ISSN1873-2518
KeywordsAntibody Formation, Antigen-Presenting Cells, Antigens, CD14, Antigens, CD34, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Female, Granulocyte-Macrophage Colony-Stimulating Factor, Hematopoietic Stem Cells, Hepatitis B Antibodies, Hepatitis B Vaccines, HIV, HIV Infections, Humans, Male, Middle Aged, Monocytes, Pilot Projects, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
Abstract

We evaluated immunologic predictors of response to HBV vaccine administered in the presence or absence of GM-CSF in HIV infected individuals. We measured peripheral blood hematopoietic progenitor, monocyte and myeloid-derived suppressor cell (MDSC) frequencies, and expression of GMCSF receptor on monocytes and MDSCs, at baseline and 4weeks after immunization in relation to antibody response. We observed higher baseline progenitor and lower monocyte frequencies among week 16 antibody responders. Week 4 decline in MDSC frequency was associated with week 16 antibody response, while administration of GM-CSF was associated with preservation of these cells. No significant differences in GM-CSF receptor expression were observed in the presence vs. absence of GM-CSF. These findings are consistent with a positive role of progenitor cells and a potential negative role of monocytes in vaccine response. Additionally, GM-CSF augmented the preservation of peripheral blood MDSC, which may contribute to the lack of improved vaccine responses.

DOI10.1016/j.vaccine.2011.02.092
Alternate JournalVaccine
PubMed ID21397720
PubMed Central IDPMC3081920
Grant ListAI 068634 / AI / NIAID NIH HHS / United States
AI 68634 / AI / NIAID NIH HHS / United States
AI 68636 / AI / NIAID NIH HHS / United States
AI038855 / AI / NIAID NIH HHS / United States
AI069495 / AI / NIAID NIH HHS / United States
AI069532 / AI / NIAID NIH HHS / United States
AI0801 / AI / NIAID NIH HHS / United States
R01 DK068361 / DK / NIDDK NIH HHS / United States
R01 DK068361 / DK / NIDDK NIH HHS / United States
R01 DK068361-05 / DK / NIDDK NIH HHS / United States
U01 AI025879 / AI / NIAID NIH HHS / United States
U01 AI025879-17 / AI / NIAID NIH HHS / United States
U01 AI038855 / AI / NIAID NIH HHS / United States
U01 AI038855-09 / AI / NIAID NIH HHS / United States
U01 AI068634 / AI / NIAID NIH HHS / United States
U01 AI068634-06 / AI / NIAID NIH HHS / United States
U01 AI068636-05 / AI / NIAID NIH HHS / United States
U01 AI069495 / AI / NIAID NIH HHS / United States
U01 AI069495-06 / AI / NIAID NIH HHS / United States
U01 AI069501 / AI / NIAID NIH HHS / United States
U01 AI069501-06 / AI / NIAID NIH HHS / United States
U01 AI069502 / AI / NIAID NIH HHS / United States
U01 AI069532 / AI / NIAID NIH HHS / United States
U01 AI069532-06 / AI / NIAID NIH HHS / United States